Gold prices steady ahead of Fed decision; weekly weakness noted
Ocugen, Inc. (NASDAQ:OCGN) announced Tuesday that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed companies to maintain a minimum closing bid price of at least $1.00 per share. The company received written notice from the Nasdaq Listing Qualifications Department on Monday confirming that its common stock closed at or above $1.00 per share for ten consecutive business days, from July 8 to July 25. Nasdaq has closed the compliance matter. According to InvestingPro data, the stock has shown significant momentum with a 39% gain over the past six months, though its beta of 4.19 indicates high volatility.
Previously, Ocugen disclosed that on December 31, 2024, it received a notice from Nasdaq stating that its common stock had traded below the $1.00 minimum closing bid price for 30 consecutive business days, putting the company at risk of delisting from The Nasdaq Capital Market. Ocugen was initially given 180 calendar days, until June 30, 2025, to regain compliance. On July 1, 2025, Nasdaq granted the company an extension through December 29, 2025. The $300.79 million market cap company is currently trading near its InvestingPro Fair Value.
The company stated that it satisfied the listing rule by maintaining the required minimum closing bid price for the specified period. As a result, Nasdaq has determined that Ocugen now meets the continued listing standards.
This information is based on a statement from the company’s Form 8-K filing with the Securities and Exchange Commission.
In other recent news, Ocugen, Inc. has made significant strides in its clinical trials and corporate developments. The company announced the dosing of the first patient in its Phase 2/3 GARDian3 clinical trial for OCU410ST, a gene therapy candidate targeting Stargardt disease. This trial will involve 51 participants, with 34 receiving a one-time subretinal injection. Additionally, the U.S. Food and Drug Administration has cleared an amendment for Ocugen’s pivotal Phase 2/3 trial for the same therapy, which has already received Rare Pediatric Disease and Orphan Drug Designations.
In corporate developments, Ocugen has expanded its advisory board by appointing three renowned retinal surgeons to advance its gene therapy programs. The company also received an additional 180-day extension from Nasdaq to meet the minimum bid price requirement of $1.00 per share, allowing it until December 29, 2025, to regain compliance. Furthermore, a merger agreement involving Ocugen’s subsidiary, OrthoCellix, and Carisma Therapeutics has been announced, aiming to create a Nasdaq-listed company focused on orthopedic diseases. This merger will concentrate on developing OrthoCellix’s NeoCart technology for repairing knee cartilage defects. These developments mark a period of active progression for Ocugen in both its clinical and corporate endeavors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.